We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 23, 2022

Rucaparib Monotherapy as First-Line Maintenance Treatment for Newly Diagnosed Ovarian Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
J. Clin. Oncol 2022 Jun 06;[EPub Ahead of Print], BJ Monk, C Parkinson, MC Lim, DM O'Malley, A Oaknin, MK Wilson, RL Coleman, D Lorusso, P Bessette, S Ghamande, A Christopoulou, D Provencher, E Prendergast, F Demirkiran, O Mikheeva, O Yeku, A Chudecka-Glaz, M Schenker, RD Littell, T Safra, HH Chou, MA Morgan, V Drochýtek, JN Barlin, T Van Gorp, F Ueland, G Lindahl, C Anderson, DC Collins, K Moore, F Marme, SN Westin, IA McNeish, D Shih, KK Lin, S Goble, S Hume, K Fujiwara, RS Kristeleit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading